Abstract Number: 1141 • 2012 ACR/ARHP Annual Meeting
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…Abstract Number: 2026 • 2012 ACR/ARHP Annual Meeting
High Prevalence of Cervical Spine and Temporomandibular Joint Involvement in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Detection of involvement of temporomandibular joints (TMJ), which are frequently affected by juvenile idiopathic arthritis (JIA), is only possible on Gadolinium enhanced MRI…Abstract Number: 1155 • 2012 ACR/ARHP Annual Meeting
A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis
Background/Purpose: Studies on outcomes of children with juvenile idiopathic arthritis-associated uveitis (JIA-U) focus on the clinical ocular exam and physical disability secondary to arthritis. This…Abstract Number: 2001 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Background/Purpose: Medication adherence and persistence have been demonstrated to have important implications for treatment effectiveness, cost, and safety. Methotrexate is one of the most commonly…Abstract Number: 1021 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging in Follow-up of Clinical Remission in Juvenile Idiopathic Arthritis
Background/Purpose: Despite clinical remission, a substantial proportion of Juvenile Idiopathic Arthritis (JIA) patients will flare after a period of inactive disease. MRI has proven to…Abstract Number: 2005 • 2012 ACR/ARHP Annual Meeting
Clinical Course and Outcomes of Children with Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Uveitis
Background/Purpose: Uveitis can lead to vision loss and blindness. Few studies focus on the outcomes of children with both juvenile idiopathic arthritis-associated uveitis (JIA-U) and…Abstract Number: 974 • 2012 ACR/ARHP Annual Meeting
Identification of Susceptibility Loci for Inflammatory Arthritis
Background/Purpose: One of the principal findings of genome wide association studies in autoimmune diseases has been the substantial overlap of genetic susceptibility loci identified. This…Abstract Number: 2007 • 2012 ACR/ARHP Annual Meeting
Radiological Peripheral Involvement At Hands, Feet and Hips in Young Adults with Polyarticular Idiopathic Juvenile Arthritis
Background/Purpose: Radiographic damage was recently considered to be a feature of poor prognosis in cases of polyarticular juvenile idiopathic arthritis (pJIA). However, most radiographic studies…Abstract Number: 760 • 2012 ACR/ARHP Annual Meeting
Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 Clinical Trial
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA), characterized by chronic arthritis associated with prominent systemic and laboratory features, also has a significant impact on the growing…Abstract Number: 2011 • 2012 ACR/ARHP Annual Meeting
ACR Criteria, Providers’ Global Rating of Change and Role of Patient Self-Report in Evaluating Change in Disease Over Time: A Patient Reported Outcomes Measurement Information System Study
Background/Purpose: As part of a longitudinal study of Juvenile Idiopathic Arthritis (JIA), providers completed clinical outcomes assessments and patients (pt) completed self-report measures at clinic…Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting
Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective. Pulmonary artery…
- « Previous Page
- 1
- …
- 17
- 18
- 19